- Home
- IOVA
as 07-26-2024 4:00pm EST
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 2.4B | IPO Year: | N/A |
| Target Price: | $25.70 | AVG Volume (30 days): | 6.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $18.33 | Next Earning Date: | 08-06-2024 |
| Revenue: | $1,904,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 13727.59% | Revenue Growth (next year): | 174.35% |
Stock Insider Trading Activity of Iovance Biotherapeutics Inc. (IOVA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rothbaum Wayne P. | IOVA | Director | Feb 20 '24 | Buy | $9.15 | 5,000,000 | $45,750,000.00 | 28,067,333 | SEC Form 4 |
| MCPEAK MERRILL A | IOVA | Director | Feb 20 '24 | Buy | $9.15 | 250,000 | $2,287,500.00 | 320,150 | SEC Form 4 |
| Dukes Iain D. | IOVA | Director | Feb 20 '24 | Buy | $9.15 | 32,000 | $292,800.00 | 54,000 | SEC Form 4 |
Latest Iovance Biotherapeutics Inc. News
IOVA Breaking Stock News: Dive into IOVA Ticker-Specific Updates for Smart Investing
Zacks
a day ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
GlobeNewswire
7 days ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Zacks
8 days ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Motley Fool
13 days ago
Is Iovance Biotherapeutics a Millionaire Maker?
Insider Monkey
18 days ago
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Stocks Loved by Analysts?
Simply Wall St.
24 days ago
Unveiling Three US Growth Companies With High Insider Ownership
MT Newswires
a month ago
Iovance Biotherapeutics Seeks European Regulator's Approval of Marketing Authorization Application for Advanced Melanoma Treatment
GlobeNewswire
a month ago
Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
Compare IOVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOVA Iovance Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.